Abstract:
Objective To explore the relationship between the expression of p57KIP2, cyclin D1, and cyclin E receptors in male breast cancer (MBC) and its clinical significance.
Methods Data of MBC cases diagnosed in The First Affiliated Hospital of Wenzhou Medical University between January 2000 and December 2016 were reviewed. Forty cases of infiltrating ductal carcinoma (IDC) and 20 cases of male ductal carcinoma in situ (DCIS) were selected, and 20 cases of gynecomastia (GYM) were selected as controls. The expression of p57KIP2, cyclin D1, and cyclin E mRNA and protein in the tissue samples obtained from IDC, DCIS, and GYM cases were measured by reverse transcription polymerase chain reaction and immunohistochemistry, respectively.
Results The expression of p57KIP2 mRNA in IDC was 0.18±0.07, which was lower than that in DCIS (0.42±0.05) and GYM (0.75±0.04). The rate of p57KIP2 positivity in IDC was 25%(10/ 40), which was lower than that in DCIS 60% (12/20) and GYM 90% (18/20). There were significant differences in the expression of p57KIP2 mRNA and protein among the three groups (P < 0.05). The expression of cyclin D1 and cyclin E mRNA in IDC was 0.92±0.12 and 0.96±0.08, which was higher than that in DCIS (0.72±0.06, 0.64±0.01) and GYM (0.38±0.03, 0.21±0.02), respectively. Cyclin D1 and cyclin E protein positive rates in IDC were 90% (36/40) and 88% (35/40), which were higher than those in DCIS 80% (16/20), 85% (17/ 20), and GYM 25% (5/20), 20% (4/20). In IDC tissues, the expression of p57KIP2, cyclin D1, and cyclin E proteins was associated with the clinical stage and histological grade (P < 0.05), and the expression of p57KIP2 protein was correlated with axillary node metastasis (P < 0.05). There was a negative correlation between the expression of p57KIP2 and cyclin D1 and between p57KIP2 and cyclin E. However, the correlation between cyclin D1 and cyclin E expression was positive (P < 0.05).
Conclusions p57KIP2, cyclin D1, and cyclin E may play an important role in the development and progression of MBC. Combined clinicopathological detection of p57KIP2, cyclin D1, and cyclin E can aid future research on MBC.